Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus

作者：Xiang, Yirong; Li, Mengtao^*; Luo, Hui; Wang, Yanhong; Duan, Xinwang; Zhao, Cheng; Zhan, Feng; Wu, Zhenbiao; Li, Hongbin; Yang, Min; Xu, Jian; Wei, Wei; Wu, Lijun; You, Hanxiao; Qian, Junyan; Yang, Xiaoxi; Huang, Can; Zhao, Jiuliang; Wang, Qian; Leng, Xiaomei; Tian, Xinping; Zhao, Yan; Zeng, Xiaofeng^*

来源：Arthritis Research and Therapy, 2021, 23(1): 20.

DOI：10.1186/s13075-020-02407-5

• Scarring alopecia
• Systemic lupus erythematosus
• Risk factor

BackgroundScarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Chinese SLE patients.MethodsSLE patients in Chinese SLE treatment and Research group (CSTAR) were recruited. Scarring alopecia was defined according to SLICC/ACR-DI which was collected during follow-up visits or via self-reported questionnaires. We collected demographic characteristics, common comorbidities, autoantibody profiles, disease activity status, major organ involvements, and treatment strategies of these patients at registry. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for scarring alopecia.ResultsWe recruited 4792 SLE patients, and 374 (7.80%) patients had scarring alopecia. Mucocutaneous lesions (OR 2.062, p <0.001), high SLICC/ACR-DI (OR 1.409, p <0.001), and positive anti-Sm (OR 1.374, p =0.029) were risk factors for scarring alopecia, while renal (OR 0.714, p =0.028) and cardio-respiratory involvements (OR 0.347, p =0.044), and immunosuppressant treatment (OR 0.675, p <0.001) were significantly negative associated with it.ConclusionsThe prevalence of scarring alopecia in SLE patients is 7.80%. Active treatment strategies should be adopted to prevent scarring alopecia occurring.

• 单位
  中国医学科学院北京协和医院; 中国人民解放军第四军医大学; 内蒙古医学院; 1; 南昌大学; 南方医科大学